tbuckley/cabot-search huggingface dataset:
Complications of local corticosteroid injections
Authors: N. L. Gottlieb
Journal: JAMA (1980)

Unusual complications associated with local microcrystalline corticosteroid injections were observed in four patients with diverse rheumatic disorders. Adverse reactions included (1) bilateral digital flexor tendon rupture following carpal tunnel injection for idiopathic median nerve compression syndrome; (2) bowstring deformity of a finger after local corticosteroid treatment of psoriatic digital flexor tendonitis; (3) carpal tunnel infection following dorsal arthrocentesis of a wrist in a patient with rheumatoid arthritis; and (4) pronounced flushing of the face, neck, and chest after intrasynovial corticosteroid injection in a patient with psoriasis and arthritis. This article considers some physiologic actions of corticosteroids possibly responsible for development of these untoward effects. (<i>JAMA</i>243:1547-1548, 1980)
The family practice model in health education
Authors: R. I. Lienke
Journal: JAMA (1970)

The American Board of Family Practice was established early in 1969. Family practice, as the nation's 20th specialty, was thus formally recognized as having a legitimate place in the health-care system. General practice was not discarded. Rather, the establishment of the American Board of Family Practice constituted a formal request to bring general practice up to date, to standardize its training program at a level equivalent to the other specialties, and to recognize competence and formal training by means of examination and certification. Thoughtful educators and physicians from many disciplines wrote and conferred for a decade in order to make a decision that would be the most appropriate for the consumers as well as the providers of primary medical care. Most any new name would have been fitting to symbolize the upgraded or specialty status of the new general practitioners. The label of family practice was chosen because it carried
Correction
Journal: BMJ (1984)

MEDICAL NEWSLambeth sickle cell information centre An information and counselling centre for patients with sickle cell disease, their relatives, and friends has opened in Lambeth (2 Stockwell Road, London SW9 9EN; tel 01 737 3588).It offers a walk in advisory service to support the existing clinical facilities at King's College Hospital and St Thomas's Hospital.The Lambeth centre, one of only five in the country, is run by local people and funded by the Lambeth Inner Cities Partnership Fund.The area covered by
Cardiac disorders in penicillin-induced anaphylaxis. Association with intravenous epinephrine therapy
Authors: T. J. Sullivan
Journal: JAMA (1982)

This report describes cardiac dysfunction in two patients experiencing penicillin-induced anaphylaxis. Telemetric monitoring of the patients' ECGs initially disclosed sinus rhythm. Immediately after intravenous (IV) injections of epinephrine chloride, ventricular premature beats and apparent accelerated idioventricular rhythm occurred in one patient and possible ventricular tachycardia occurred in the other. These observations demonstrate the value of ECG monitoring of patients during anaphylaxis and emphasize the potential hazards of administering epinephrine by the IV route in this clinical setting. (<i>JAMA</i>1982;248:2161-2162)
THE PHARMACOPEIA AND THE PHYSICIAN.CHAPTER XVII.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.
Authors: Nirmish Singla, Layton Woolford, Christina Stevens, Vanina Tcheuyap, Oreoluwa Onabolu, Zhiqun Xie, Renee McKay, Tao Wang, Alana Christie, Jeffrey Gahan, Aditya Bagrodia, Ganesh Raj, Arthur I. Sagalowsky, Yair Lotan, Jeffrey A Cadeddu, Vitaly Margulis, Payal Kapur, James Brugarolas
Journal: Journal of Clinical Oncology (2019)

651 Background: Patient-derived xenograft (PDX) models of renal cell carcinoma (RCC) preserve the biological features of patient tumors, providing a platform for biomarker identification and preclinical drug testing. We sought to identify predictors of successful tumor engraftment and evaluate the prognostic value of engraftment in patients with RCC using a robust murine PDX platform. Methods: 1,200 specimens derived from nephrectomy, thrombectomy, metastasectomy, or biopsy were orthotopically (renally) implanted into NOD/SCID mice between 2008-2018. Non-RCC pathology was excluded. Stable engraftment was defined by successful passage of tumor tissue at least twice with histologic confirmation. Clinicopathologic characteristics were stratified by engraftment status, and multivariate (MVA) logistic regression was used to identify predictors of engraftment. Kaplan-Meier and Cox regression analyses were used to assess the prognostic value of engraftment on patient overall (OS) and disease-free (DFS) survival. Results: 1,003 independent PDX lines derived from 770 RCC patients were included. 157 (15.6%) lines successfully engrafted and exhibited higher tumor grade, stage, size, and presence of sarcomatoid or rhabdoid components. Whole exome sequencing was performed on 230 PDX lines. On MVA, sarcomatoid (OR 5.71, p &lt; 0.001), rhabdoid (OR 2.79, p = 0.046), and advanced stage (OR 1.72, p = 0.049) were significant predictors for engraftment, while high grade and metastatic tumor source were significant only on UVA. Engraftment was associated with poor OS (HR 2.11, p &lt; 0.001) and DFS (HR 1.85, p = 0.020) in patients after controlling for sarcomatoid, rhabdoid, grade, stage, and age on MVA. Conclusions: Aggressive RCC biology correlates with successful engraftment in PDX models. Engraftment remains independently predictive of OS and DFS even after controlling for adverse pathologic features. Engraftment in mice may illuminate aspects of tumor biology not captured by clinicopathologic variables and provide insight into novel determinants of tumor aggressiveness and metastasis. Efforts are underway to elucidate genomic drivers of engraftment.
STATISTICS OF STATE BOARD EXAMINATIONS
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy
Authors: Gary H. Lyman, Jessica Malone Kleiner
Journal: Journal of the National Comprehensive Cancer Network (2007)

Three different practice guidelines for the myeloid growth factors were recently published by major professional organizations. A comprehensive review and comparison of the guidelines using a priori structured content criteria and a previously validated quality appraisal tool are reported. The final recommendations from these guidelines are consistent for primary prophylaxis with the colony-stimulating factors (CSFs) when the risk of febrile neutropenia is in the range of 20% or greater. All 3 guidelines also recommend prophylactic use of myeloid growth factors in patients with important factors increasing individual risk of neutropenic complications. The recommendation that patients receiving regimens associated with lower risk should have CSF use guided by individual risk assessment is also consistent. Critical quality appraisal indicates that the scope, purpose, stakeholder involvement, and applicability of these guidelines differ little. The American Society of Clinical Oncology and European Organization for Research and Treatment of Cancer guidelines place more emphasis on comprehensive literature reviews, and the National Comprehensive Cancer Network guidelines are more current based on systematic annual updates. Presentation clarity also favors National Comprehensive Cancer Network guidelines, with recommendations generally presented as both text and algorithmic diagram.
Accuracy of Medicare reimbursement for cardiac arrest
Authors: D. C. Hsia
Journal: JAMA (1990)

Diagnosis related group (DRG) 129 consists exclusively of discharges having a principal diagnosis of<i>International Classification of Diseases, Ninth Revision, Clinical Modification</i>code 427.5 (cardiac arrest). It excludes patients with more specific diagnoses (eg, myocardial infarction and arrhythmia) or patients admitted for a different reason and who subsequently experience cardiac arrest. This study used a one-stage sample design to select all DRG 129 discharges from random hospitals, stratified by their annual number of DRG 129 bills. Using blinded techniques, medical records specialists reabstracted the<i>International Classification of Diseases</i>codes for 857 medical records. For the bills that were not coded DRG 129 on reabstraction, physicians classified the incorrect bills by clinical situation and reason for error. Diagnosis related group 129 had significantly higher rates of coding errors and upcoding than other DRGs. Of discharges erroneously billed to DRG 129, 42.1% of the patients entered the hospital for heart disease other than cardiac arrest and 55.2% died after entering the hospital for other diseases. Attending physicians need to distinguish between the "immediate cause" of death for the death certificate and the "principal diagnosis" for reimbursement purposes. (<i>JAMA</i>. 1990;264:59-62)
Open segmental tibial fracture
Authors: O. E. Aufranc
Journal: JAMA (1966)

<h3>Dr. Turner:</h3> A 17-year-old boy was riding his motorcycle and collided with an automobile. His right tibia was crushed between the running board of the automobile and the frame of his motorcycle. He arrived at the Massachusetts General Hospital emergency ward 30 minutes following his injury and was found to have a blood pressure of 80/40 mm Hg with a pulse rate of 140 beats per minute. Intravenous fluids were started, blood was sent for cross matching, and his injuries were then further assessed. There was no evidence of head, spine, chest, or abdominal trauma, and the patient's skeletal injuries were limited to the right leg. There was a 6-inch open wound over the anterolateral aspect of the right leg. There was a second, 1 1/2-inch open wound more distally, over the medial face of the tibia (Fig. 1). A segmented piece of the tibia 5 inches long presented between
P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment
Authors: S. Kaneko, K. Ito, S. Yuki, K. Harada, M. Yagisawa, K. Sawada, A. Ishiguro, O. Muto, K. Hatanaka, H. Okuda, A. Sato, Y. Sasaki, M. Nakamura, T. Sasaki, Y. Tsuji, T. Ando, K. Kato, T. Wakabayashi, M. Kotaka, Y. Takahashi, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2021)
LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues
Authors: Keefe T. Chan, Sreeja B. Asokan, Samantha J. King, Tao Bo, Evan S. Dubose, Wenjin Liu, Matthew E. Berginski, Jeremy M. Simon, Ian J. Davis, Shawn M. Gomez, Norman E. Sharpless, James E. Bear
Journal: The Journal of Experimental Medicine (2014)
Commentaire des travaux de C.-W. Ko et al. pp. 849 et P. Magno et al. pp. 876
Journal: Endoscopy (2007)

See also: A new stapler-based full-thickness transgastric access closure: results from an animal pilot trialEndoscopy 2007; 39(10): 876-880DOI: 10.1055/s-2007-966896 See also: Preliminary pneumoperitoneum facilitates transgastric access into the peritoneal cavity for natural orifice transluminal endoscopic surgery: A pilot study in a live porcine modelEndoscopy 2007; 39(10): 849-853DOI: 10.1055/s-2007-966844
6. Parenteral carbenicillin
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postprandial Drowsiness
Authors: Eduardo H. Rubinstein
Journal: JAMA (1972)

<h3>To the Editor.—</h3> The problem of the postprandial drowsiness outlined by Dr. Kleitman (219:1485, 1972) prompted successive letters by Drs. Hauri (220:1135, 1972) and Regenstein (221:601, 1972). I would like now. to introduce another factor for consideration: the possible role of the intestinal hormones.<sup>1</sup> The presence of food in the gut releases intestinal hormones: cholecystokinin (CCK) and secretin.<sup>2</sup>Our observations<sup>3</sup>indicated that during the period of release, the incidence of sleep (in the cat) was significantly increased. Also, the intraduodenal instillation of small amounts of releasing agents, eg, corn oil, was followed, after a variable latency, by sleep with rapid eye movement (REM) periods of earlier onset and longer duration than average. Moreover, the intravenous infusion of the intestinal hormones, especially cholecystokinin, was associated, during the one-hour infusion, with long-lasting episodes of deep and REM sleep. This effect of the hormones varied depending on the time of
Cerebral angiography as a guide for therapy in isolated central nervous system vasculitis
Authors: R. L. Stein
Journal: JAMA (1987)

VASCULITIS is an inflammatory disorder of blood vessels that can affect both the arterial and venous limbs of the vascular tree. The process is often segmental, and it can affect vessels of all sizes. It is characterized histologically by infiltration of the affected vessel wall by neutrophils or mononuclear cells, local destruction of the vessel wall, extravasation of red blood cells into surrounding tissue, fibrinoid necrosis, and thrombosis. Immunofluorescent microscopy often demonstrates the presence of immunoglobulin(s), complement component(s), and fibrin deposited in the vessel wall. The outcome of the vasculitic lesion is often infarction and necrosis of tissue distal to the site.<sup>1</sup>Diagnosis of vasculitis is confirmed by identification of the pathognomonic histological lesion. Under many clinical circumstances, however, it is not feasible to obtain tissue for histopathology. This is the situation, for example, in isolated central nervous system vasculitis, wherein a cortical or leptomeningeal biopsy might not be
Pédiatrie, Lyon
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Measles in HIV-Infected Children, United States
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Archives of General Psychiatry, Chicago
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
Authors: Daniel Vargas Almeida, Cleyton Z. Oliveira, Andrey Soares, RODRIGO COUTINHO MARIANO, Denis L Jardim, Diogo Assed Bastos, Fernando C. Maluf, Gustavo Werutsky, Fernando Sabino M Monteiro, Vinicius Carrera Souza, Guillermo de Velasco, Andre P. Fay, Andre Deeke Sasse, Fabio A. B. Schutz
Journal: Journal of Clinical Oncology (2019)

4579 Background: Although surgery is the cornerstone in the treatment of most cases of localized kidney cancer, up to 30% of patients will experience disease recurrence at three years of follow-up. Three RCTs with VEGFR TKIs (ASSURE, PROTECT and ATLAS) failed to demonstrate improvement in disease-free survival (DFS). Only S-TRAC trial showed a significant improvement in DFS, and was approved by the Food and Drug Administration (FDA). However, the matter remains controversial among genitourinary oncologists. Therefore, we performed a meta-analysis to better evaluate the potential benefit of adjuvant VEGFR TKIs after curative intent nephrectomy. Methods: Eligible studies were searched in PubMed databases and limited to phase 3 RCT published from January 1996 to December 2018 of US FDA-approved VEGFR TKIs reporting on patients with RCC treated in the adjuvant setting. A summary hazard-ratio (HR) of disease-free survival (DFS) was calculated using 95% CIs by random-effects or fixed-effects models on the basis of the heterogeneity of included studies. Results: Four RCT (ASSURE, S-TRAC, PROTECT and ATLAS trials) were selected for analysis, including a total of 4,820 patients. A VEGFR TKI (sunitinib, sorafenib, pazopanib or axitinib) was administered in 2,737 patients, and 2,083 received placebo. The summary DFS HR for the overall population was 0.89 (95% CI 0.79-1.00; p = 0.06). When including the report of the ASSURE with the sub-group analysis with high-risk patient population (n = 3,946), the summary HR for DFS was 0.84 (95% CI 0.75-0.95, p = 0,0044). No evidence of publication bias was found. Conclusions: This is the first meta-analysis including the four RCTs in RCC adjuvant setting. This meta-analysis failed to demonstrate improvement in DFS for patients receiving a VEGFR TKI after curative intent nephrectomy. A modest benefit in DFS was observed in a selected sub-group of patients with higher risk for recurrence. There is no data regarding overall survival.